BridgeBio Pharma EBIT

BridgeBio Pharma (BBIO) currently reports a EBIT of $-610M as of June 2026. That compares with $-640M in the prior-year period — up 5.4% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore BridgeBio Pharma's EBIT history and peer comparisons.

BridgeBio Pharma's EBIT increased from $-640M to $-610M — a 5.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BridgeBio Pharma's EBIT of $-610M is lower than the Healthcare sector average of $23B. That is roughly 102.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

BridgeBio Pharma reported $-610M in EBIT as of June 2026. That compares with $-640M in the prior-year period — up 5.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-610M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for BridgeBio Pharma, and consider following BBIO for alerts when major investors trade the stock.